BioCryst Announces RAPIVAB Pediatric sNDA Acceptance
BioCryst Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for a pediatric indication of…
Read More...
Read More...